Goldman Sachs
PRLD icon

Goldman Sachs’s Prelude Therapeutics PRLD Stock Holding History

Goldman Sachs’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$809K Buy
236,469
+118,992
+101% +$312K ﹤0.01% 5249
2025
Q4 		$341K Buy
117,477
+38,150
+48% +$64.4K ﹤0.01% 5799
2025
Q3 		$114K Sell
79,327
-69,851
-47% -$70K ﹤0.01% 6060
2025
Q2 		$121K Sell
149,178
-6,037
-4% -$5.23K ﹤0.01% 5781
2025
Q1 		$119K Buy
155,215
+6,889
+5% +$6.43K ﹤0.01% 5752
2024
Q4 		$189K Buy
148,326
+53,165
+56% +$70.5K ﹤0.01% 5658
2024
Q3 		$197K Buy
95,161
+20,238
+27% +$93.7K ﹤0.01% 5464
2024
Q2 		$285K Buy
74,923
+7,496
+11% +$30.5K ﹤0.01% 5127
2024
Q1 		$320K Sell
67,427
-2,038
-3% -$7.93K ﹤0.01% 4943
2023
Q4 		$297K Buy
69,465
+1,777
+3% +$5.41K ﹤0.01% 5010
2023
Q3 		$209K Buy
67,688
+43,900
+185% +$165K ﹤0.01% 5034
2023
Q2 		$107K Sell
23,788
-25,708
-52% -$154K ﹤0.01% 5348
2023
Q1 		$282K Buy
49,496
+33,732
+214% +$206K ﹤0.01% 5143
2022
Q4 		$95.2K Sell
15,764
-5,971
-27% -$38.3K ﹤0.01% 5488
2022
Q3 		$144K Sell
21,735
-22,560
-51% -$152K ﹤0.01% 5593
2022
Q2 		$232K Buy
44,295
+20,205
+84% +$103K ﹤0.01% 5572
2022
Q1 		$166K Sell
24,090
-89,245
-79% -$816K ﹤0.01% 5946
2021
Q4 		$1.41M Buy
113,335
+104,676
+1,209% +$1.7M ﹤0.01% 4546
2021
Q3 		$271K Sell
8,659
-9,958
-53% -$322K ﹤0.01% 5561
2021
Q2 		$533K Sell
18,617
-24,892
-57% -$886K ﹤0.01% 5169
2021
Q1 		$1.89M Buy
+43,509
New +$2.89M ﹤0.01% 4050
2020
Q4 		– Sell
-83,200
Closed -$2.51M – 5657
2020
Q3 		$2.51M Buy
+83,200
New +$2.35M ﹤0.01% 3411

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs's PRLD Position: Q1 2026 in Review

Goldman Sachs increased its Prelude Therapeutics (PRLD) stake by 101% in Q1 2026, buying an estimated $312K and bringing the position to 236,469 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #5249.

Goldman Sachs first reported a position in PRLD in Q3 2020 and has held it in 22 quarters since. The position peaked at $2.51M in Q3 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Goldman Sachs held 236,469 shares of Prelude Therapeutics worth $809K as of Q1 2026.
  • Goldman Sachs bought 118,992 Prelude Therapeutics shares in Q1 2026, an estimated $312K.
  • Prelude Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5249 holding.
  • Goldman Sachs first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Prelude Therapeutics position peaked at $2.51M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.